COVID-19

May 28, 2020

Developing Covid-19 Vaccines at Pandemic Speed | Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial | Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

May 21, 2020

Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 | Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract

May 14, 2020

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study | Preventing a Parallel Pandemic — A National Strategy to Protect Clinicians’ Well-Being | Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Arterial thromboembolic complications

May 12, 2020

Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis | Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State | Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

May 7, 2020

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young | Hyperinflammatory shock in children during COVID-19 pandemic | Interpreting Diagnostic Tests for SARS-CoV-2 | The Ecology of Being Human by Dickson Despommier

The Ecology of Being Human

By Dickson Despommier —
Since their establishment some 11,000 years ago, as of 2020, cities with populations greater than one hundred thousand have evolved and grown to accommodate some 60% of us (that’s 4.4 billion individuals). The trend is clear. In another 50 years it is estimated that over 80% of the human population will live in cities.

May 5, 2020

ACE inhibitors and ARBS not linked to COVID-19 infection or severity | Effective treatment of severe COVID-19 patients with tocilizumab | Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy

April 30, 2020

Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease | Adaptive COVID-19 Treatment Trial “ACTT” (NIAID) | SIMPLE I Trial results (Gilead) | Remdesivir in Chinese adults with severe COVID-19

April 28, 2020

Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 | Human leukocyte antigen susceptibility map for SARS-CoV-2

April 24, 2020

The Recovery Trial is a multi-arm multi-stage adaptive trial with mortality as the primary endpoint together with a 10 year follow up period linked to the electronic health records of ~6900 Covid-19 patients in the UK enrolled to date treated with either: placebo or ritonavir/lopinavir or steroids or azithromycin or hydroxy-chloroquine.

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States. 

Scroll to Top